In the present study, the antitumor efficacy of Fx1 relied on immune cells, suggesting BCL6 expression in MC38 or B16F10 tumor cells likely did not reflect a direct antitumor effect, though inhibiting BCL6 in tumors may benefit tumor growth resistance as well. This evidence concerns the gene BCL6 and neoplasm.